Reshma Kewalramani, Vertex CEO (Photo by Barry Chin/The Boston Globe via Getty Images)

November 16, 2023 06:15 AM ESTUpdated November 17, 03:19 PM

In a world first, Vertex, CRISPR win UK approval for CRISPR-edited therapy to treat sickle cell disease, beta-thalassemia

Amber Tong

Senior Editor

Lei Lei Wu

News Reporter

Vertex and CRISPR Therapeutics have won the first-ever approval for a therapy created with CRISPR gene editing, as the UK drug regulator MHRA greenlights their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In a world first, Vertex, CRISPR win UK approval for CRISPR-edited therapy to treat sickle cell disease, beta-thalassemia

Amber Tong

Senior Editor

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

In a world first, Ver­tex, CRISPR win UK ap­proval for CRISPR-edit­ed ther­a­py to treat sick­le cell dis­ease, be­ta-tha­lassemia

Senior Editor

News Reporter

Sign up to read this article for free.

In a world first, Vertex, CRISPR win UK approval for CRISPR-edited therapy to treat sickle cell disease, beta-thalassemia